Sponsored by Janssen Pharmaceuticals 
Join us for two sessions over lunch.
The first: Advancing Clinical & Economic Outcomes in Schizophrenia: The Janssen LAI Portfolio, is a discussion of how a holistically focused approach to treatment of serious mental illness can result in both financial savings and improved outcomes measures, including HEDIS standards presented by Jack Sheehan, Ph.D., MBA, Senior Director, Neuroscience Real World Value & Evidence, Janssen Scientific Affairs.
The second: Measurable Improvements In Care: The Power Of Collaboration with Suzanne F. Conroy, MS, Senior Director, National Clinical Value Optimization, Optum Health Behavioral Solutions, and Jason Kan, PharmD, Vice President Of Product, Genoa Healthcare.